Literature DB >> 33737695

Pathological findings after third- and second-generation everolimus-eluting stent implantations in coronary arteries from autopsy cases and an atherosclerotic porcine model.

Suguru Migita1,2, Daisuke Kitano2, Yuxin Li3, Yutaka Koyama1,2, Sayaka Shimodai-Yamada1, Akira Onishi4, Daiichiro Fuchimoto5, Shunichi Suzuki5, Yoshiyuki Nakamura6, Taka-Aki Matsuyama7, Seiichi Hirota8, Masashi Sakuma9, Masahiko Tsujimoto10, Atsushi Hirayama11, Yasuo Okumura2, Hiroyuki Hao12.   

Abstract

Pathological changes after third-generation drug-eluting stent implantation remain unclear. We compared the tissue responses of coronary arteries after the implantation of third-generation abluminal biodegradable-polymer everolimus-eluting stent (3rd EES) and second-generation durable-polymer EES (2nd EES) using autopsy specimens and an atherosclerotic porcine model. We compared the histology of stented coronary arteries obtained by autopsy performed 1-10 months after 3rd EES (n (number of cases) = 4, stent-implanted period of 3-7 months) and 2nd EES (n (number of cases) = 9, stent-implanted period of 1-10 months) implantations. The ratio of covered stent struts was higher with 3rd EESs than with 2nd EESs (3rd; 0.824 ± 0.032 vs. 2nd; 0.736 ± 0.022, p = 0.035). Low-density lipoprotein receptor knockout minipigs were stented with 3rd or 2nd EES in the coronary arteries and the stented regions were investigated. The fibrin deposition around the 2nd EES was more prominent. Additionally, higher density of smooth muscle cells was confirmed after the 3rd EES implantation. Pathological examination after the 3rd EES demonstrated a combination of less fibrin deposition and more rapid acquisition of well-developed neointima as compared to the 2nd EES at autopsy and the atherosclerotic porcine model.

Entities:  

Year:  2021        PMID: 33737695     DOI: 10.1038/s41598-021-85740-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  34 in total

1.  Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.

Authors:  Gregg W Stone; Ali Rizvi; Krishnankutty Sudhir; William Newman; Robert J Applegate; Louis A Cannon; James T Maddux; Donald E Cutlip; Charles A Simonton; Poornima Sood; Dean J Kereiakes
Journal:  J Am Coll Cardiol       Date:  2011-04-21       Impact factor: 24.094

2.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

Authors:  Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani
Journal:  J Am Coll Cardiol       Date:  2006-05-05       Impact factor: 24.094

3.  Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.

Authors:  Sebastian Kufner; Michael Joner; Anna Thannheimer; Petra Hoppmann; Tareq Ibrahim; Katharina Mayer; Salvatore Cassese; Karl-Ludwig Laugwitz; Heribert Schunkert; Adnan Kastrati; Robert A Byrne
Journal:  Circulation       Date:  2019-01-15       Impact factor: 29.690

4.  Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.

Authors:  Lisette Okkels Jensen; Per Thayssen; Evald Høj Christiansen; Michael Maeng; Jan Ravkilde; Knud Nørregaard Hansen; Henrik Steen Hansen; Lars Krusell; Anne Kaltoft; Hans Henrik Tilsted; Klara Berencsi; Anders Junker; Jens Flensted Lassen
Journal:  J Am Coll Cardiol       Date:  2016-02-23       Impact factor: 24.094

5.  Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.

Authors:  Aloke V Finn; Michael Joner; Gaku Nakazawa; Frank Kolodgie; John Newell; Mike C John; Herman K Gold; Renu Virmani
Journal:  Circulation       Date:  2007-04-16       Impact factor: 29.690

6.  A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.

Authors:  Martin B Leon; Laura Mauri; Jeffrey J Popma; Donald E Cutlip; Eugenia Nikolsky; Charles O'Shaughnessy; Paul A Overlie; Brent T McLaurin; Stuart L Solomon; John S Douglas; Michael W Ball; Ronald P Caputo; Ash Jain; Thaddeus R Tolleson; Bernard M Reen; Ajay J Kirtane; Peter J Fitzgerald; Kweli Thompson; David E Kandzari
Journal:  J Am Coll Cardiol       Date:  2010-02-09       Impact factor: 24.094

7.  Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).

Authors:  David E Kandzari; Laura Mauri; Jeffrey J Popma; Mark A Turco; Paul A Gurbel; Peter J Fitzgerald; Martin B Leon
Journal:  JACC Cardiovasc Interv       Date:  2011-05       Impact factor: 11.195

8.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.

Authors:  Adnan Kastrati; Julinda Mehilli; Jürgen Pache; Christoph Kaiser; Marco Valgimigli; Henning Kelbaek; Maurizio Menichelli; Manel Sabaté; Maarten J Suttorp; Dietrich Baumgart; Melchior Seyfarth; Matthias E Pfisterer; Albert Schömig
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

9.  Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.

Authors:  Gregg W Stone; Mark Midei; William Newman; Mark Sanz; James B Hermiller; Jerome Williams; Naim Farhat; Ronald Caputo; Nicholas Xenopoulos; Robert Applegate; Paul Gordon; Roseann M White; Krishnankutty Sudhir; Donald E Cutlip; John L Petersen
Journal:  Circulation       Date:  2009-01-26       Impact factor: 29.690

10.  Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.

Authors:  Sjoerd H Hofma; Jan Brouwer; Matthijs A Velders; Arnoud W J van't Hof; Pieter C Smits; Michel Queré; Cornelis Jan de Vries; Adrianus J van Boven
Journal:  J Am Coll Cardiol       Date:  2012-07-31       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.